•  
  •  
  •  
  •  

2023-03-21 16:35:20

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • ICRA reaffirms rating of Acknit Industries Ltd
  • Faisal Islamic Bank, set to revolutionize Egypt's digital banking experience with Intellect Global Consumer Banking's CBX Platform
  • Thomas Cook India & SOTC Travel partner with LTIMindtree to launch 'Green Carpet'
  • NMDC Ltd announces price revision of Iron Ore from March 21, 2023
  • Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome

Keywords Selected:  INE790G01031

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Shilpa Medicare Ltd gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
  • Shilpa Medicare Ltd registers Bengaluru facility with Ministry of Health, UAE
  • Shilpa Medicare Ltd launches Capecitabine 1000 MG dispersible tablet
  • Shilpa Medicare Ltd's Unit IV, Jadcherla, Telangana facility has received Health Canada GMP Approval
  • Shilpa Medicare completes Human Clinical Studies of High Concentration Biosimilar Adalimumab
  • Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA Remote Record Review
  • Shilpa Medicare Limited, Unit 1, Raichur API facility receives Russian GMP
  • Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP
  • Shilpa Medicare Ltd recommends dividend of Rs. 1.10
  • US FDA Inspection of Shilpa Medicare Limited, Unit VII, Analytical Services Division
  • Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept
  • Shilpa Biologicals partners with Mylab
  • Shilpa Medicare receives approval in Europe for Pemetrexed Injection
  • Shilpa Medicare Limited launches PRUCALSHIL (Prucalopride) Orally Disintegrating Strips 1 Mg And 2 Mg in India
  • US FDA concludes remote record review of Unit 3 of Shilpa Medicare Ltd
  • Shilpa Medicare Ltd enters Phase I Clinical Trial for its New Biological Entity, recombinant Human Albumin
  • Shilpa Medicare raises over Rs. 297 crore from marquee investors
  • Shilpa Medicare Limited approves preferential allotment to investors

Latest Post

  • ICRA reaffirms rating of Acknit Industries Ltd
  • Faisal Islamic Bank, set to revolutionize Egypt's digital banking experience with Intellect Global Consumer Banking's CBX Platform
  • Thomas Cook India & SOTC Travel partner with LTIMindtree to launch 'Green Carpet'
  • NMDC Ltd announces price revision of Iron Ore from March 21, 2023
  • Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022